Introduction
Phosphoinositide 3-kinases (PI3K) are lipid kinases that phosphorylate phosphoinositides at the 3' position of the inositol ring leading to the generation of PI[3]P, PI[3,4]P 2 and PI[3,4,5]P 3 (PI3Ps). These new lipids are rapidly produced upon cell stimulation and play a role of second messenger during cell growth, survival, migration and membrane tracking. They transmit the extracellular signal by targeting cytoplasmic proteins to the plasma membrane, stimulating enzymatic activities or regulating dissociation of protein complexes (for review see . The molecular basis for these intracellular events has been recently unravelled. These lipids bind to speci®c conserved peptidic sequences leading to a change in protein conformation or intracellular localization. For example, protein anchoring to the plasma membrane occurs through association with the Pleckstrin Homology (PH) domain of the cytoplasmic protein. In addition to these various eects, PI3Ps are involved in speci®c signalling pathways. For example PI[3,4]P 2 and PI[3,4,5]P 3 are important transmitters of growth and survival stimuli and act by targeting PH domain containing-proteins such as the survival serine/ threonine kinase Akt. On the other hand PI[3]P is thought to play a role in membrane tracking, via association with FYVE homology domain-containing proteins involved in this process .
The PI3K family comprises at least 12 members. They are subgrouped in three distinct classes depending on their substrate speci®city. Enzymes of type I phosphorylate PI, PI[4]P and PI [4, 5] . Type I enzymes are extensively studied as they were originally identi®ed associated with tyrosine kinases such as growth factor receptors and products of oncogenes. This class comprises four members, all of them forming a heterodimer. PI3Ka, b and d share the regulatory subunit (p85a, p85b, p55 and p50) with a unique catalytic subunit (p110a, b and d) and they are known to interact with speci®c domains phosphorylated on tyrosine residues. In contrast, PI3Kg is composed of a p110g catalytic subunit, plus a regulatory subunit called p101 without any homology with known peptidic sequences and it is activated by G-protein-coupled receptors. Type I PI3K are eectors of the small G protein Ras and are thus involved in several Ras-dependent signalling events including cell transformation and survival. While PI3Kg and d are mainly expressed in haematopoietic tissues, a and b are ubiquitously expressed .
Most investigation about type I PI3Ks focused on the a form. Recently an important function for this enzyme has also been reported during embryogenesis in the mouse (Bi et al., 1999) . Very little is known however, about the function of other members of the subfamily. Using a microinjection approach with speci®c neutralizing antibodies, we reported a speci®c role for PI3Ka (Roche et al., 1994b) and for PI3Kb (Roche et al., 1994b) during mitogenesis in murine ®broblasts. With a similar approach in macrophages, also concluded to speci®c functions for PI3Ka, b and d in cell responses initiated by CSF-1 with a role for PI3Ka in S phase entry and an involvement of b and d in cell migration. The molecular basis for such speci®city is currently unknown and it represents an important issue that needs to be addressed. PI3Kg has been described as an important mediator of cell responses initiated by heterotrimeric GTP-binding protein-coupled receptor (GPCR) including the activation of the serine/threonine MAP kinases (MAPK) (Lopez-Ilasaca et al., 1997) . Considering the important role for MAPK in the induction of DNA synthesis (Graves et al., 1995) , one would predict a function for PI3Kg in cell growth as induced by GPCR. Nevertheless several reports including ours, suggest that some of these mitogens utilize PI3Kb and/or a rather than g for signalling (Hawes et al., 1996; Laargue et al., 1999; Roche et al., 1998) . The reason for this is unclear but it is likely that p110g and/or p101 are not expressed in the cell lines used for these studies and that a and b would de®ne an alternative route for GPCR-induced PI3K signalling. This hypothesis has been recently con®rmed by p110g gene disruption experiments performed in mice: in contrast to p110a, p110g 7/7 mice were viable and showed a speci®c defect in thymocyte development and neutrophils activation in response to GPCR agonists (Hirsch et al., 2000; Li et al., 2000; Sasaki et al., 2000) .
Given the important functions of type I PI3K, one would expect that they also act as oncogenes or that their activity is deregulated in cancer. Indeed a viral oncogenic form of p110 that resembles p110a has been identi®ed in birds (Chang et al., 1997) . Expression of a constitutive active form of bovine p110a is transforming in rodent ®broblasts (Klippel et al., 1998 ). An oncogenic form of type I PI3K, which involves a mutated form of the regulatory subunit p85a, has also been described in mice (Jimenez et al., 1998) . Expression of this allele associates with endogenous p110 and increases its activity in a constitutive manner, leading to cell transformation. This suggests the existence of several Figure 1 Increase in PI3Ka(p85a-p110a) and PI3Kb(p85a-p110b) activities in human primary tumours. (a) An example of in vitro PI3K activities obtained from the lysate of a tumour (T) relative to the normal epithelium (C) of the same patient. PI3Ka, b, and g were immunoprecipitated with indicated p110 antibodies followed by an in vitro lipid kinase assay using PI:PI[4]P:PI[4,5]P 2 as substrates. Is shown a 4 h exposure autoradiography of the products separated on thin layer chromatography as described in the method section. The PI3K immunoprecipitated as well as the position of the various lipids is shown. (b) Increase in PI3Ka (grey boxes) and PI3Kb (white boxes) activities in 19 colon (no 1 ± 10) and bladder (no 11 ± 19) carcinoma relative to their normal epithelium. Increase in PI3K activity (fold control) was calculated by the ratio between the amount of PIP 3 obtained from the tumour relative to the one obtained from the normal epithelium as described in a. Tumours no 1 ± 3 were of B stage, no 3 ± 8 of C stage and no 8 ± 10 of D stage of the Duke's classi®cation. No 11 ± 14 were super®cial tumours of the bladder, stage pTa, no 15 ± 17 stage pT1, no 18 and no 19 were invasive tumours of the bladder stage pT2 and pT3 respectively. (c) Increase in p110a and p110b protein levels in human carcinoma cells as assessed by Western blotting. PI3Ka and PI3Kb were immunoprecipitated with speci®c p110 antibodies as indicated, from tissue lysates of the tumour (T) and the adjacent normal epithelium (C). The level of p110a, p110b and p85a was analysed by Western blotting with speci®c antibodies and is shown. T1 and T3 were human colon tumours and C1 and C3 the corresponding normal epithelia, T2 and T4 were human bladder tumours and C2 and C4 their corresponding normal epithelia. Similar results were obtained with three additional carcinoma. (d) Increase in p110a and p110b protein levels in human carcinoma cells as assessed by immunohistological staining. Two sections of a bladder tumour were immunostained with a speci®c antibody to p110a (ap110a.1) and to p110b (ap110b.3) as indicated. Speci®c immunostaining is shown in brown and cell nuclei are stained in blue A function for PI3Ka and PI3Kb in human carcinoma C Be Â nistant et al mechanisms for deregulating the PI3K pathway. However the status of PI3K in human cancer is ill de®ned.
Recently the human locus of p110a, PIK3CA, was found to be ampli®ed in primary ovarian tumour cells and it has been implicated as an oncogene in these cancer cells (Shayesteh et al., 1999) . Therefore type I PI3K may also be implicated in human tumour progression. In agreement with this notion, high PI3K activity was found in human colon (Phillips et al., 1998) and breast carcinoma (Gershtein et al., 1999) . However neither the PI3K involved nor the mechanism for deregulation has been investigated. In this report we have addressed the function for type I PI3Ks in cancer cell growth using a microinjection approach and we concluded to a speci®c function for PI3Ka in cell survival and an involvement of PI3Kb in DNA synthesis.
Results

Activation of PI3Ka and PI3Kb in human colon cancer cells
Deregulation of type I PI3Ks was ®rst investigated in primary tumours. Type I PI3K activities were determined in lysates of human carcinoma biopsy relative to adjacent normal epithelium of 19 human carcinoma ( Figure 1a ). 7/10 colon and 8/9 bladder carcinoma displayed a strong increase in a and b enzymatic activity with a maximum observed for bladder tumours (up to 18-fold). Interestingly PI3K activation was observed in tumours of all stages including super®cial (stage PTa) and invasive bladder tumours (PT2-3), early and advanced colon. A modest increase in PI3Kg activity could be detected in some tumours (see for example Figure 1a , top panels), however we concluded that PI3Ka and b are the major enzymes targeted in these cancers as: (i) PI3Kg activity corresponded to 5 ± 20% of that observed with PI3Ka or b, (ii) the observed activation was of lower range, (iii) not frequently observed and (iv) ®nally p110g protein was hardly detected by Western blotting suggesting that it is poorly expressed in these tumours (not shown). Altogether these results pointed to an increase in PI3Ka and PI3Kb activities in human carcinoma cells. Whether the observed PI3K activity was due to a higher level of p110a and p110b was next investigated by Western blotting. A strong increase in p110 levels were observed in ®ve out of 12 tumours tested ( Figure  1b and data not shown). This was accompanied by an increase in co-associated p85a regulatory subunit. Interestingly some tumours displayed an increase in 
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Figure 2 Increase in PI3Ka(p85a-p110a) and PI3Kb(p85a-p110b) activities in human carcinoma cells. (a) PI3Ka, b and g activities in human colon cancer cell lines. PI3Ka, b and g and the small GTP-binding protein Ras were immunoprecipitated with ap110a.1, ap110b.3 and ap110g and Y13259 respectively, from lysates of indicated adenocarcinoma cell lines, and followed by an in vitro lipid kinase assay using PI as a substrate. Is shown a 4 h exposure autoradiography from the products separated on thin layer chromatography as described in Materials and methods section. The position of PI3P is indicated. (b) PI3Ka (top panel) and PI3Kb (bottom panel) were immunoprecipitated with speci®c antibodies from the lysate of indicated adenocarcinoma cell lines, followed by an in vitro lipid kinase assay using PI as a substrate.
Produced PI3P was quanti®ed and compared with the lowest value obtained among dierent cell lines (non-transformed ®broblasts, NIH3T3) and PI3K activity (arbitrary units) was calculated as the ratio between both values. The results from three independent experiments have been averaged, and the mean and standard deviation of the mean are shown. (c) Expression of p110a, p110b, p110g and PLCg in various colon cancer cell lines. p110a, p110b, p110g and PLCg protein levels were assessed by Western blotting using ap110a.2 and ap110b.3, monoclonal ap110g and aPLCg antibodies respectively. Catalytic subunits were immunoprecipitated from the indicated cell lysates before Western blotting analysis. The position of p110a and p110b, p110g and PLCg are shown Oncogene A function for PI3Ka and PI3Kb in human carcinoma C Be Â nistant et al PI3K activities without any dierence in p110 protein levels (not shown), suggesting the existence of an additional mechanism for PI3K deregulation. An immunohistological approach was next used in order to con®rm the increase in p110a and b levels and an example is shown in Figure 1c : p110a and p110b expression was detected using ap110a.1 and ap110b.3 antibodies respectively on sections of a bladder tumour of stage pTa (tumour sample no. 12, see Figure 1a ). Strong p110a and p110b signals were detected in tumour cells in agreement with our biochemical analyses. In our conditions, no staining was detected in normal surrounding tissue ( Figure 1c ) nor with a control antibody (not shown), con®rming signal speci®city. Interestingly, p110a staining decorated cellcell contact suggesting that this enzyme is mainly located at the plasma membrane and must be in an activated state. p110b was also detected at the cell-cell contact but it also showed a substantial cytoplasmic staining and was not detected in all tumour cells. Deregulation of type I PI3K activities were next con®rmed in human colon carcinoma cell lines. Catalytic p110 subunits a, b and g were immunoprecipitated from non-transformed ®broblasts (as a control) and the carcinoma cell lines CaCo2, CO115, HCT 116, LS 174T and WiDr, followed by an in vitro lipid kinase assay. We found that these cells mainly express PI3Ka and PI3Kb while PI3Kg was hardly detected ( Figure  2a ). All transformed cell lines exhibited high PI3Ka and PI3Kb activities (Figure 2 ) however HCT 116 and LS 174T showed the highest PI3Ka activity (eightfold that observed in ®broblasts and 2 ± 3-fold that in WiDr). On the other hand, a threefold higher PI3Kb activity was obtained in WiDr relative to HCT 116. All type I PI3Ks are known as eectors of the small GTP-binding protein Ras and PI3K activity associated with Ras was also measured in order to con®rm enzymatic activation. As shown in Figure 2a , PI3K activity associated with Ras was readily detected in several cancer cells, in particular for WiDr and LS 174T cells, that exhibit the highest PI3Ka and b activity, respectively. The level of expressed p110 was next investigated. As observed in ovarian cancer cells (Shayesteh et al., 1999 ) a 2 ± 3-fold higher p110a level was detected in LS 174T compared to WiDr (Figure 1c) . On the other hand, a 2.5-fold higher p110b level was detected in both CO115 and WiDr cells in agreement with the observed activities. Increase in p110 level was speci®c to the a and b forms as p110g was not detected by this approach and the level of PLCg, another signalling molecule involved in cell growth control (Roche et al., 1996) , was not changed in most cell lines (Figure 2c) . Altogether, this suggests that PI3Ka and PI3Kb are deregulated in human colon cancer cells, and this involves an increase in p110 protein level. Interestingly, no increase in p110s levels was observed in LS 174T cells compared to normal ®broblasts while exhibiting higher activity (Figure 2c ). This suggests that intrinsic catalytic activation also participates in PI3K deregulation.
A function for PI3Ka and PI3Kb in carcinoma cell growth and survival
The function for PI3K activation in cancer cell growth control was next investigated. In a ®rst approach, PI3K activities were inhibited in colon cancer cell lines studied by treating cells with various concentrations of pharmacological inhibitor LY294002 that does not discriminate between PI3Ks. Cell cycle progression was recorded by adding Bromo deoxyUridine (BrdU) into the medium for 18 h that will incorporate into the nucleus during new DNA synthesis. In these conditions, about 80% of carcinoma cells tested had incorporated BrdU and this response was aected by LY294002 (Figure 3 ). Interestingly some cell types were highly sensitive to drug treatment such as WiDr and CO115 (75% inhibition) while COLO 205 cells were rather insensitive to PI3K inhibition (38% inhibition caused by 20 mM of inhibitor). Therefore PI3K activity is required for induction of DNA synthesis in some, but not all colon carcinoma cells.
The speci®c function of PI3Ka and PI3Kb was next analysed using a microinjection approach. For this purpose WiDr, HCT 116 and CO115 cells were chosen because of their high sensitivity to LY294002 drug treatment, and their suitability for microinjection (attachment to glass coverslips and`monolayer-like' cell growth when sub-con¯uent). Neutralizing antibodies speci®c to p110a and p110b respectively, were injected into the cytoplasm of exponentially growing cells; BrdU was next added to the medium for 18 h in order to record cells that had newly synthesized DNA. These antibodies speci®cally inhibit respective enzymes both in vitro and in vivo (Roche et al., 1998 ). An example for such experiments is shown in Figure 4a . While 80% of non injected WiDr cells had incorporated BrdU, seven out of 10 injected cells with antip110b antibody shown on this ®eld had not incorporated BrdU, suggesting an involvement for PI3Kb in the induction of de novo DNA synthesis. Statistic analysis is shown in Figure 4b BrdU incorporation (%) Figure 3 Eect of the PI3K inhibitor LY294002 on de novo DNA synthesis of human adenocarcinoma cell lines. BrdU incorporation of cells treated or not (black boxes) with 2 mM (grey boxes) and 20 mM (white boxes) of LY294002. Cells were grown onto glass coverslips and treated or not for 72 h with PI3K inhibitors and BrdU were added during the last 18 h into the medium as a marker of DNA synthesis. BrdU incorporation was analysed as described in the Materials and methods section and DNA synthesis was calculated by the following formula: % of cells=(number of BrdU-positive cells/ total number of cells). Are shown the results of an experiment performed in duplicate and representative of two separate experiments p110b antibodies as not reproduced with a neutralizing antibody speci®c to p110g (M PuceÂ at and S Roche, submitted). The function of PI3Ka was also analysed by a similar approach (Roche et al., 1994b) . Surprisingly, ap110a-injected cells had shrunk with a condensed or fragmented nucleus (see Figure 5a ), suggesting that cells underwent apoptosis. The presence of apoptotic cells was con®rmed by cell staining with annexin V-coupled to FITC (not shown). Statistic analysis is shown in Figure 5b : 70% of ap110a-injected HCT 116 and WiDr cells went into apoptosis. A similar eect was observed in CO115-injected cells, although not as dramatic (22% of injected cells went into apoptosis). This eect was not due to the microinjection technique since it was reproduced when treating cells with a high concentration of LY294002. It was also speci®c to this antibody as not reproduced with anti-p110b or anti-p110g antibody. Finally antip110a-induced cell death was reversed when pretreating cells with 0.1 mM z-VAD-fmk, a general inhibitor of proteases of the caspase family, known to mediate apoptotic signals (Nunez et al., 1998) . From these data, we concluded that PI3Ka plays an important role in carcinoma cell survival.
Discussion
We have investigated the role of PI3Ka and PI3Kb in human carcinoma cell growth. First our data suggests that these enzymes are activated in colon and bladder 
Apoptosis (%) cancer cells consistent with an important function for carcinogenesis. Increase in activity may probably involve an overexpression of p110a and p110b in some of these tumours, as suggested by our Western blotting and immunostaining analyses. Overexpression of the catalytic subunit alone may be sucient to generate a fully active enzyme as immunodepletion experiments suggested that p85a is in excess in these cancer cells (unpublished data). However, additional mechanisms may also participate in enzymatic deregulation, including tyrosine kinase overexpression and mutation of Ras or the p85 regulatory subunit. In favour with this hypothesis, high PI3K activity associated with Ras and phosphotyrosine containing proteins was observed both in transformed cell lines and primary tumours (not shown). Both mechanisms lead to an increase in intrinsic enzymatic activity (Backer et al., 1992; Rodriguez-Viciana et al., 1996) and therefore may take part of the observed PI3K deregulation. Previous reports attributed a function for PI3Ks in cell division, survival, cell dedierentiation (Phillips et al., 1998) , migration and tumour invasion (Kobayashi et al., 1999; Shaw et al., 1997) . Most of these investigations did not discriminate between a and b, precluding from speci®c functions. Rather, these authors used an activated form of p110a suggesting that PI3Ka may be responsible for most of these functions in epithelial cells. However speci®city between type I PI3K may be lost by the use of a constitutive active enzyme, which may stimulate all PI3K-dependent signalling pathways. Rather we have used an antibody microinjection approach in order to assess the speci®c function of PI3Ka and PI3Kb. These antibodies have been previously shown to inhibit speci®c enzymatic activity (Roche et al., 1998 (Roche et al., , 1994b and will neutralize enzymatic activity in vivo without aecting related lipid kinases, thus allowing speci®c function assessment (Hill et al., 2000; McIlroy et al., 1997; Roche, 1998; Roche et al., 1994b; . These experiments led to show a requirement for PI3Kb in de novo DNA synthesis of cancer cells. This con®rms a role for PI3K in the growth of lung (Moore et al., 1998) , ovarian (Shayesteh et al., 1999) and colon cancer cells (this study) as suggested by the use of pharmacological PI3K inhibitor LY29004 and previously shown in murine ®broblasts (Roche et al., 1998) . Nevertheless some other carcinoma cells included in our study were poorly sensitive to this inhibitor, indicating that either a PI3K resistant to this drug is activated in these cells or that an important eector is overexpressed or constitutively activated, thus bypassing the need of PI3K for cell growth. Therefore some, but not all colon carcinoma may require PI3Kb for de novo DNA synthesis. It is of some note that LY294002 is derived from quercetin (Vlahos et al., 1994) and several avonoids are inhibitors of PI3-kinase. Thereforē avonoids could have some protective roles against colon cancer cell growth.
Our microinjection study also revealed a speci®c function for PI3Ka in cancer cell survival, which may contribute to primary tumour growth. This is again consistent with the conclusion drawn by the use of the LY29004 inhibitor in other cancer cells (Moore et al., 1998; Shayesteh et al., 1999) . Interestingly the group of Backer recently reported a speci®c function of PI3Ka during EGF-induced actin nucleation of a rat breast cancer cell line (Hill et al., 2000) . This conclusion would favour a function for this enzyme in carcinoma invasion and is in accordance with a PI3Ka localization at the leading edge of the tumour where it invades the bladder. The function of PI3Ka in short-term cytoskeletal changes induced by EGF was not investigated in our case and it may probably exist in human colon cancer cells. Therefore PI3Ka may probably regulate several biological processes including cell survival and migration. Nevertheless the lipid kinase activation observed at early stages of the tumour development points to an essential function of PI3Ka in primary tumour growth.
Finally this report con®rms speci®city among type I PI3Ks as previously suggested (Christoforidis et al., 1999; Deora et al., 1998; Hill et al., 2000; Roche et al., 1998 Roche et al., , 1994b . The reason for speci®city is not known yet but one can envision a distinct intracellular localization between a and b. Our immunostaining studies revealed some speci®c localization between both enzymes, suggesting that this might be part of the speci®city. The second hypothesis we favour is the existence of speci®c ligands for p110 subunits. p110a and p110b peptidic sequence only share 50% of identity and speci®c interactors of p110b have been recently identi®ed including the bg subunits of Gi protein (Kurosu et al., 1997; Maier et al., 1999) . Therefore, important mitogens for these cancer cells may utilize seven trans-membrane receptors coupled to G protein for PI3Kb recruitment as recently demonstrated in non transformed ®broblasts (Roche et al., 1998) and suggested in SW480 colon cancer cells (Graness et al., 1998) . On the other hand Ras was also described as an important regulator of cell survival in epithelial cells which involves its eector PI3Ka (Khwaja et al., 1997) . Association of Ras occurs via a conserved sequence in p110 N-terminus (RodriguezViciana et al., 1996) . While such a sequence is also present in p110b to some extent (Rodriguez-Viciana et al., 1996) , convincing data for an association between PI3Kb and Ras for cell survival is still missing. A speci®c function for PI3Ka in cell survival could come from a preferential association with Ras.
Materials and methods
Carcinoma samples and cell lines
Tumour biopsies were obtained from 19 patients and included nine transitional cell carcinoma of the bladder and 10 colon adenocarcinoma (CA). Healthy epithelium was removed at a distance from the tumour and showed normal histological characteristics as assessed by standard heamotoxylin-eosin staining procedure. Bladder tumours were classi®ed according to the 1997 TNM classi®cation and for clarity purposes, CA were classi®ed in four stages according to Duke's classi®cation. Human carcinoma cell lines include CaCo2, CO115, COLO 205, HCT 116, LS 174T and WiDr which were kindly provided by Dr PeÁ legrin (Centre de Recherche en CanceÂ rologie, CRLC, Montpellier, France).
Antibodies
The antibodies ap110a.1 and 2 were raised against the last 16 carboxy terminal amino acids and amino acids 776 ± 791 of the bovine brain p110a subunit respectively (Roche et al., 1994b) ; ap110b2 and 3 were raised against amino acids 738 ± 752 and 420 ± 435 of the human p110b respectively (Roche et al., 1998) ; ap110g was raised against amino acid 742 ± 756 of human p110g. Polyclonal ap85a and Y13 259 anti-Ras monoclonal antibody were previously described (Roche et al., 1998) . Anti-PLCg antibody was raised against the SH2 domains of PLCg as described in (Roche et al., 1996) . Antiphosphotyrosine 4G10 was purchased from UBI. Polyclonal antibodies were puri®ed as described in (Roche et al., 1994b) and concentrated up to 1 ± 2 mg/ml using centricon columns (Minicon) according to the manufacturer's instruction for microinjection studies.
Biochemistry
Lysates from cell culture and tissue biopsies were performed using ice-cold LB buer (20 mM Tris [pH 8], 150 mM NaCl, 1% Nonidet P-40, 1% aprotinin, 20 mM leupeptin, 0.1 mM sodium orthovanadate, 10 mM NaF and 1 mM DTT) as described in (Roche et al., 1994a) . Methods for immunoprecipitation and Western blotting were described in (Roche et al., 1994a) . The same amount of protein cell lysate was used in all cases with an excess of antibody, in order to precipitate all enzyme copies. In vitro lipid kinase assays were performed essentially as described in (Roche et al., 1998) . Lysates were precleared before immunoprecipitation and lipid kinase assay. After immunoprecipitation, a mixture of phosphatydilserine-PI (1 : 1) or phosphatydilserine-PI-PI[4]P-PI[4,5]P 2 (3 : 1 : 1 : 1) (Sigma) was used as substrates as indicated. Products were separated by chromatography on silica gel 60 plates impregnated with 1% potassium oxalate-1 mM EDTA in chloroform-methanol-acetone-glacial acid aceticwater (60 : 20 : 23 : 18 : 11) for 2 h. Labelled products were detected by autoradiography and quanti®ed using a phosphorimager.
Immunohistology
Four mm of formalin-®xed paran embedded human tissue sections were immunolabelled with the antibody speci®c to p110a (ap110a.1) and to p110b (ap110b.3). Detection of the bound antibodies was performed using a catalyzed signal ampli®cation system from Dako Corporation, using 3,3'-diaminobenzidine tetrahydrochloride (DAB) as a chromogen.
Cell culture and microinjection
Adenocarcinoma cell lines were cultured in RPMI 1640 medium (Eurobio) containing glutamine, antibiotics (penicillin and streptomycin) and 5% foetal calf serum (FCS) at 378C in a humidi®ed 5% CO 2 atmosphere. For LY294002 (Sigma) treatment, cells were grown for 2 days in the absence or in the presence of various concentrations of LY294002 as indicated. DNA synthesis was next recorded by adding bromodeoxyuridine (BrdU) (0.1 mM) into the medium for an extra 18 h. Fresh medium containing or not LY298002 was replaced every 24 h in order to avoid inhibitor degradation during the time of incubation. Cells were microinjected as described in (Roche et al., 1994b) . Brie¯y cells were seeded onto glass coverslips and grown for 48 h. Typically 100 cells were then injected with anity puri®ed antibody into the cytoplasm 18 h before ®xation using a semi-automatic Eppendorf transjector. DNA synthesis was recorded by adding BrdU into the medium and cells were then ®xed for immunostaining. In some cases cells were treated with the caspases inhibitor z-VAD-fmk (Chemicon) 1 h prior to microinjection or treating cells with LY294002.
Immunofluorescence
Coverslips were washed once with PBS and ®xed for 5 min with ice-cold methanol (Sigma). Injected cells were stained either with¯uorescein-or rhodamine-conjugated anti-rabbit antibody (ICN) (1 : 50). To analyse DNA synthesis, cells were incubated for 10 min with 1.5 M HCl, washed three times with PBS, stained with monoclonal (1 : 50) anti-BrdU antibody (Pharmingen), followed by rhodamine conjugated antimouse antibody (ICN). All coverslips were ®nally washed in PBS containing 10 mM Hoechst 33258 (®nal concentration 1 mg/ml; Sigma), rinsed in water, inverted and mounted in Moviol (Hoechst) on glass slides. Slides were viewed with an Axiophot¯uorescence microscope. The percentage of injected cells that incorporated BrdU, for each coverslip, was calculated by the following formula: per cent of BrdUpositive cells=(number of BrdU-positive injected cells/ number of injected cells)6100. Apoptotic cells were recorded by staining nucleus with propidium iodine or the membrane with FITC-conjugated annexin V for 10 min (Sigma).
